Diarrhoea News and Research RSS Feed - Diarrhoea News and Research

NPS MedicineWise urges child care centres to increase awareness around misuse of antibiotics in young children

NPS MedicineWise urges child care centres to increase awareness around misuse of antibiotics in young children

NPS MedicineWise has written to child care centres across Australia to enlist their support in responding to the growing problem of antibiotic resistance. Child care staff are well placed to help with education and increase awareness around the misuse of antibiotics in young children. [More]
Study sheds more light on how bacteria rapidly causes infectious diseases

Study sheds more light on how bacteria rapidly causes infectious diseases

Researchers at Umea University are first to discover that bacteria can multiply disease-inducing genes which are needed to rapidly cause infection. [More]
Cabozantinib drug can extend lives of patients with advanced renal cell carcinoma

Cabozantinib drug can extend lives of patients with advanced renal cell carcinoma

Data presented today at the American Society of Clinical Oncology congress showed that cabozantinib, a next generation tyrosine kinase inhibitor (TKI) can extend the lives of patients by nearly two years following failure of one or more anti-angiogenic therapies almost five months longer than everolimus, a current standard of care therapy. [More]
Spider venom helps investigate pain signals experienced by irritable bowel syndrome patients

Spider venom helps investigate pain signals experienced by irritable bowel syndrome patients

Spiders have helped researchers from Australia and the US discover a new target for irritable bowel syndrome pain. [More]
Bacteriophage combinations show therapeutic potential in reducing C. difficile infections

Bacteriophage combinations show therapeutic potential in reducing C. difficile infections

A new University of Leicester study has confirmed the therapeutic potential of bacteriophage combinations to treat highly infectious bacteria C. difficile infections (CDI) while retaining a healthy gut. [More]
Global increase in sale of baby formula raises concerns about health of infants, mothers

Global increase in sale of baby formula raises concerns about health of infants, mothers

A new study from The Australian National University has found a global boom in the sale of infant and baby formula, especially in China and Southeast Asia, raising concerns about the health of millions of mothers and their babies. [More]
University of Leicester researcher awarded grant to develop bacteriophages to target infant Shigella

University of Leicester researcher awarded grant to develop bacteriophages to target infant Shigella

A University of Leicester researcher has been awarded funding to develop bacteriophages to target bacterial infant diarrhoea in the developing world where it causes significant mortality. [More]
ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients

ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients

Data from the 48-week ART trial, presented today at the Digestive Disease Week meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe, steroid-dependent active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants and / or biologics when treated with between five and eight sessions with Adacolumn. [More]
New data visualization platform identifies shortfalls in vaccine introduction and coverage

New data visualization platform identifies shortfalls in vaccine introduction and coverage

As the 69th World Health Assembly discusses progress on the Global Vaccine Action Plan, a new data visualization platform--from the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health--provides stark numbers on where shortfalls exist in vaccine introduction and coverage. [More]
New frozen faecal bank increases chances of curing a chronic health condition

New frozen faecal bank increases chances of curing a chronic health condition

A new frozen faecal bank that could save hundreds of lives and dramatically improve the quality of life of many more has been established at a Portsmouth hospital. [More]
Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion. [More]
Janssen gets positive CHMP opinion for IMBRUVICA (ibrutinib) to treat patients with previously untreated CLL

Janssen gets positive CHMP opinion for IMBRUVICA (ibrutinib) to treat patients with previously untreated CLL

Janssen-Cilag International NV today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a Positive Opinion, recommending broadening the existing marketing authorisation for ibrutinib as a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). [More]
AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca today reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC), at the European Lung Cancer Conference (ELCC) 2016. Late-breaker presentations reinforced the efficacy and safety profile for osimertinib previously seen in the AURA clinical trials programme. [More]
RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). [More]
Shigella dysenteriae pathogen probably originated in Europe, genetic study reveals

Shigella dysenteriae pathogen probably originated in Europe, genetic study reveals

The largest genetic study on the bacterium responsible for epidemic dysentery has revealed that the Shigella dysenteriae pathogen, which remains a real scourge in Africa and Asia, probably originated in Europe. [More]
Cobimetinib with vemurafenib may have added benefit in melanoma with BRAF V600 mutation

Cobimetinib with vemurafenib may have added benefit in melanoma with BRAF V600 mutation

Cobimetinib (trade name: Cotellic) has been approved since November 2015 in combination with vemurafenib for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation. [More]
Researchers describe antibiotic resistance as either selfish or co-operative

Researchers describe antibiotic resistance as either selfish or co-operative

Trace concentrations of antibiotic, such as those found in sewage outfalls, are enough to enable bacteria to keep antibiotic resistance, new research from the University of York has found. The concentrations are much lower than previously anticipated, and help to explain why antibiotic resistance is so persistent in the environment. [More]
New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib). [More]
Study assesses health problems related to food hypersensitivity

Study assesses health problems related to food hypersensitivity

A study by researchers at the University of Southampton and Southampton General Hospital, is the first to assess the prevalence of two different types of food hypersensitivity and the risk factors associated with them. [More]
ViiV Healthcare presents positive results from LATTE-2 study at CROI

ViiV Healthcare presents positive results from LATTE-2 study at CROI

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive results from the LATTE-2 study at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. Headline results were announced in November 2015. [More]
Advertisement